Medpace Holdings Inc (MEDP) Short Interest Update

Medpace Holdings Inc (NASDAQ:MEDP) saw a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 1,526,552 shares, a decline of 45.7% from the February 28th total of 2,812,050 shares. Based on an average daily volume of 675,905 shares, the short-interest ratio is presently 2.3 days. Approximately 5.6% of the shares of the company are sold short.

MEDP traded up $0.12 during midday trading on Monday, hitting $58.88. The stock had a trading volume of 266,800 shares, compared to its average volume of 673,758. The firm has a market cap of $2.11 billion, a P/E ratio of 22.73, a P/E/G ratio of 1.91 and a beta of 1.62. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.69 and a quick ratio of 0.69. Medpace has a 1 year low of $35.00 and a 1 year high of $71.66.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 25th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.07. The business had revenue of $192.12 million during the quarter, compared to analyst estimates of $184.66 million. Medpace had a return on equity of 17.66% and a net margin of 11.27%. Medpace’s revenue for the quarter was up 70.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.39 earnings per share. On average, equities analysts anticipate that Medpace will post 2.64 earnings per share for the current year.

In related news, CFO Jesse J. Geiger sold 25,037 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $60.00, for a total value of $1,502,220.00. Following the sale, the chief financial officer now directly owns 25,037 shares in the company, valued at approximately $1,502,220. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jesse J. Geiger sold 12,000 shares of the business’s stock in a transaction dated Friday, March 29th. The shares were sold at an average price of $58.20, for a total value of $698,400.00. Following the completion of the sale, the chief financial officer now owns 25,037 shares in the company, valued at $1,457,153.40. The disclosure for this sale can be found here. Insiders have sold a total of 705,800 shares of company stock worth $44,657,456 over the last quarter. Company insiders own 29.50% of the company’s stock.

A number of hedge funds have recently made changes to their positions in MEDP. LS Investment Advisors LLC bought a new position in shares of Medpace during the fourth quarter valued at approximately $46,000. SHANDA ASSET MANAGEMENT HOLDINGS Ltd bought a new position in shares of Medpace during the fourth quarter valued at approximately $87,000. State of Alaska Department of Revenue bought a new position in shares of Medpace during the fourth quarter valued at approximately $92,000. NumerixS Investment Technologies Inc bought a new position in shares of Medpace during the fourth quarter valued at approximately $119,000. Finally, We Are One Seven LLC bought a new position in shares of Medpace during the fourth quarter valued at approximately $130,000. Hedge funds and other institutional investors own 83.17% of the company’s stock.

MEDP has been the subject of a number of recent analyst reports. BidaskClub lowered Medpace from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 18th. Zacks Investment Research lowered Medpace from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. ValuEngine raised Medpace from a “hold” rating to a “buy” rating in a report on Thursday, January 10th. TheStreet lowered Medpace from a “b” rating to a “c” rating in a report on Friday, March 22nd. Finally, Wolfe Research assumed coverage on Medpace in a report on Tuesday, April 2nd. They set an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $51.50.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/16/short-interest-in-medpace-holdings-inc-medp-declines-by-45-7.html.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Featured Article: Bear Market – How and Why They Occur

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.